Showing 1821-1830 of 2526 results for "".
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of
- Bausch + Lomb Provides Update on Completion of Xiidra Acquisitionhttps://modernod.com/news/bausch-lomb-provides-update-on-completion-of-xiidra-acquisition/2481791/Bausch + Lomb announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (HSR Act) with respect to the
- Optometry Giving Sight Kicks Off 2023 World Sight Day Challengehttps://modernod.com/news/optometry-giving-sight-kicks-off-2023-world-sight-day-challenge/2481779/To support its mission to eradicate uncorrected refractive error through the growth and expansion of optometry around the world,
- Penn Medicine Neuroscientists Identify Brain Mechanism that Drives Focus Despite Distractionshttps://modernod.com/news/penn-medicine-neuroscientists-identify-brain-mechanism-that-drives-focus-despite-distractions/2481770/In a new study published in Neuron, neuroscientists in the Perelman School of Medicine at the University of Pennsylvania sought to illuminate the neural mechanism that helps the brain decide whether to focus visual
- Laboratoires Théa Acquires ProQR Therapeutics' Sepofarsen and Ultevursenhttps://modernod.com/news/laboratoires-thea-acquires-proqr-therapeutics-sepofarsen-and-ultevursen/2481765/ProQR Therapeutics and Laboratoires Théa announced an agreement in which ProQR will divest its late stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will receive an initial payment of €12.5 million ($13.7 m
- Glaucoma Treatment Research at Missouri S&T Receives NIH Fundinghttps://modernod.com/news/glaucoma-treatment-research-at-missouri-st-receives-nih-funding/2481759/The Missouri University of Science and Technology (S&T) announced that the National Institutes for Health (NIH) has awarded an R01 grant to Professor Hu Yang, PhD, who is S&T’s Doshi Endowed Department Chair of Chemical and Biochemical Engineering. The grant will prov
- HelpMeSee and USAID Partner to Train New Cataract Specialists to Provide Surgical Care for India's Cataract Blindhttps://modernod.com/news/helpmesee-and-usaid-partner-to-train-new-cataract-specialists-to-provide-surgical-care-for-indias-cataract-blind/2481752/HelpMeSee announced a new partnership with the United States Agency for International Development (USAID) American Schools and Hospitals Abroad (ASHA) initiative to train 100 new cataract specialists to help restore sight to India's cataract blind. Through this agreement, ASHA has p
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302https://modernod.com/news/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302/2481747/Opthea announced that the American Medical Association’s United States Adopted Names (USAN) Council has approved the nonproprietary drug name “sozinibercept” for the company’s lead biologic drug candidate, OPT-302. Sozinibercept (OPT-302) is
- Study Identifies How Diabetes Slows Healing in the Eyehttps://modernod.com/news/study-identifies-how-diabetes-slows-healing-in-the-eye/2481742/Investigators from Cedars-Sinai have provided new understanding of how diabetes delays wound healing in the eye, identifying for the first time two related disease-associated changes to the cornea, according to a company news release.
- BVI Expands IOL Capacity with New Facility in Belgiumhttps://modernod.com/news/bvi-expands-iol-capacity-with-new-facility-in-belgium/2481738/BVI has announced the opening of a new facility in Liège, Belgium that increases the company's IOL business capacity. BVI says the facility will unlock new growth opportunities while reinforcing the company’s environmental, social, and governance (ESG) leaders